title: An integrated city-driven perinatal HIV prevention program covering 1.8 million pregnant women in Shenzhen, China, 2000 to 2010.
abstract: BACKGROUND
  Despite the scale-up of prevention of mother-to-child transmission (PMTCT) programs worldwide, the translation from research studies into public health policy has been slow. This report details the experiences of a city-driven PMTCT program in China using existing health resources.
  
  
  METHODS
  The PMTCT program was devised to hospital based and city-wide. It achieves full use of available resources: the local Centers for Disease Control and Prevention, the Infectious Disease Hospital, Maternal and Child Health Hospitals, and all qualified comprehensive hospitals.
  
  
  RESULTS
  From 2000 to 2010, 1,843,122 pregnant women attended prenatal care or labor and delivery services. Overall, 97.4% received pretest HIV counseling, and 96.2% were tested for HIV. Among the 81.1% (1,495,122) of women who attended prenatal clinics, 97.2% (1,452,753) received pretest counseling and 95.7% (1,430,799) were tested for HIV. Among the 18.9% (348,000) of women with an undocumented HIV status at labor and delivery, 98.6% (343,038) received pretest counseling, and 98.1% (341,371) were tested for HIV. In total, 229 women were determined HIV positive for a prevalence of 1.3 per 10,000 pregnant women. Among the 107 HIV-infected women who carried to delivery, 87.9% received antiretroviral prophylaxis for themselves and their infants. Among the 58 women who were identified HIV positive at labor, 10.3% of mothers and 72.4% of infants received antiretroviral prophylaxis. The estimated mother-to-child transmission rate was 5.3% (95% confidence interval, 2.2%-10.7%).
  
  
  CONCLUSIONS
  With appropriate integration, existing health care resources are adequate for a comprehensive city-driven PMTCT program in an area with a low HIV prevalence.
authors.affiliation: Shenzhen Center for Disease Control and Prevention, Shenzhen, China.
authors.forename: Junmin
authors.initials: J
authors.lastname: Song
authors.forename: Tiejian
authors.initials: T
authors.lastname: Feng
authors.forename: Marc
authors.initials: M
authors.lastname: Bulterys
authors.forename: Dan
authors.initials: D
authors.lastname: Zhang
authors.forename: Christine
authors.initials: C
authors.lastname: Korhonen
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Shi
authors.forename: Xiaohui
authors.initials: X
authors.lastname: Wang
authors.forename: Jinquan
authors.initials: J
authors.lastname: Cheng
authors.forename: Lin
authors.initials: L
authors.lastname: Chen
authors.forename: Hanwu
authors.initials: H
authors.lastname: Ma
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D002681:China / Q000453:epidemiology; D003376:Counseling / Q000458:organization & administration*; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control*; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control* / Q000706:statistics & numerical data; D008297:Male; D008427:Maternal Health Services / Q000458:organization & administration*; D056990:Post-Exposure Prophylaxis; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000453:epidemiology / Q000517:prevention & control*; D011295:Prenatal Care; D015995:Prevalence; D015397:Program Evaluation
chemical_list: D019380:Anti-HIV Agents